Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS (2023) CBTRUS Statistical Report: primary brain and other Central Nervous System tumors diagnosed in the United States in 2016–2020. Neuro Oncol 25:iv1–iv99. https://doi.org/10.1093/neuonc/noad149

Article  PubMed  PubMed Central  Google Scholar 

Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, Kleinschmidt-DeMasters BK, Perry A, Reifenberger G, Stupp R, von Deimling A, Weller M (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV. Acta Neuropathol 136:805–810. https://doi.org/10.1007/s00401-018-1913-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O’Neill BP, Buckner JC, Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD, Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508. https://doi.org/10.1056/NEJMoa1407279

Article  CAS  PubMed  PubMed Central  Google Scholar 

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alnahhas I, Alsawas M, Rayi A, Palmer JD, Raval R, Ong S, Giglio P, Murad MH, Puduvalli V (2020) Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis. Neurooncol Adv 2:vdaa082. https://doi.org/10.1093/noajnl/vdaa082

Article  PubMed  PubMed Central  Google Scholar 

Young JS, Morshed RA, Hervey-Jumper SL, Berger MS (2023) The surgical management of diffuse gliomas: current state of neurosurgical management and future directions. Neuro Oncol 25:2117–2133. https://doi.org/10.1093/neuonc/noad133

Article  PubMed  PubMed Central  Google Scholar 

Delgado-Martin B, Medina MA (2020) Advances in the knowledge of the Molecular Biology of Glioblastoma and its impact in patient diagnosis, stratification, and treatment. Adv Sci (Weinh) 7:1902971. https://doi.org/10.1002/advs.201902971

Article  CAS  PubMed  Google Scholar 

Zhang K, Wang XQ, Zhou B, Zhang L (2013) The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis. Fam Cancer 12:449–458. https://doi.org/10.1007/s10689-013-9607-1

Article  CAS  PubMed  Google Scholar 

Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O’Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L, Network TR (2013) The somatic genomic landscape of glioblastoma. Cell 155:462–477. https://doi.org/10.1016/j.cell.2013.09.034

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang H, Zhang X, Liu J, Chen W, Guo X, Wang Y, Wang Y, Xing H, Liang T, Shi Y, Liu D, Yang T, Xia Y, Li J, Wu J, Liu Q, Qu T, Guo S, Li H, Zhang K, Li Y, Jin S, Zhao D, Wang Y, Ma W (2024) Clinical roles of EGFR amplification in diffuse gliomas: a real-world study using the 2021 WHO classification of CNS tumors. Front Neurosci 18:1308627. https://doi.org/10.3389/fnins.2024.1308627

Article  PubMed  PubMed Central  Google Scholar 

Olympios N, Gilard V, Marguet F, Clatot F, Di Fiore F, Fontanilles M (2021) TERT promoter alterations in Glioblastoma: a systematic review. Cancers (Basel) 13. https://doi.org/10.3390/cancers13051147

Giunco S, Padovan M, Angelini C, Cavallin F, Cerretti G, Morello M, Caccese M, Rizzo B, d’Avella D, Della Puppa A, Chioffi F, De Bonis P, Zagonel V, De Rossi A, Lombardi G (2023) Prognostic role and interaction of TERT promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients. ESMO Open 8:101570. https://doi.org/10.1016/j.esmoop.2023.101570

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han F, Hu R, Yang H, Liu J, Sui J, Xiang X, Wang F, Chu L, Song S (2016) PTEN gene mutations correlate to poor prognosis in glioma patients: a meta-analysis. Onco Targets Ther 9:3485–3492. https://doi.org/10.2147/OTT.S99942

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS (2011) An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115:3–8. https://doi.org/10.3171/2011.2.jns10998

Article  PubMed  Google Scholar 

Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, Group AL-GS (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401. https://doi.org/10.1016/S1470-2045(06)70665-9

Article  CAS  PubMed  Google Scholar 

Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, Shonka N, Gilbert MR, Sawaya R, Prabhu SS, Weinberg J, Lang FF, Aldape KD, Sulman EP, Rao G, McCutcheon IE, Cahill DP (2014) IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 16:81–91. https://doi.org/10.1093/neuonc/not159

Article  CAS  PubMed  Google Scholar 

Roder C, Stummer W, Coburger J, Scherer M, Haas P, von der Brelie C, Kamp MA, Lohr M, Hamisch CA, Skardelly M, Scholz T, Schipmann S, Rathert J, Brand CM, Pala A, Ernemann U, Stockhammer F, Gerlach R, Kremer P, Goldbrunner R, Ernestus RI, Sabel M, Rohde V, Tabatabai G, Martus P, Bisdas S, Ganslandt O, Unterberg A, Wirtz CR, Tatagiba M (2023) Intraoperative MRI-Guided resection is not Superior to 5-Aminolevulinic Acid Guidance in newly diagnosed glioblastoma: a prospective controlled Multicenter Clinical Trial. J Clin Oncol 41:5512–5523. https://doi.org/10.1200/JCO.22.01862

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dono A, Zhu P, Takayasu T, Arevalo O, Riascos R, Tandon N, Ballester LY, Esquenazi Y (2024) Extent of Resection Thresholds in Molecular Subgroups of Newly Diagnosed Isocitrate Dehydrogenase-Wildtype Glioblastoma. Neurosurgery https://doi.org/10.1227/neu.0000000000002964

Ji SY, Kim JW, Park CK (2019) Experience profiling of fluorescence-guided surgery I: gliomas. Brain Tumor Res Treat 7:98–104. https://doi.org/10.14791/btrt.2019.7.e38

Article  PubMed  PubMed Central  Google Scholar 

Drexler R, Sauvigny T, Schuller U, Eckhardt A, Maire CL, Khatri R, Hausmann F, Hanzelmann S, Huber TB, Bonn S, Bode H, Lamszus K, Westphal M, Duhrsen L, Ricklefs FL (2023) Epigenetic profiling reveals a strong association between lack of 5-ALA fluorescence and EGFR amplification in IDH-wildtype glioblastoma. Neurooncol Pract 10:462–471. https://doi.org/10.1093/nop/npad025

Article  PubMed  PubMed Central  Google Scholar 

Coburger J, Scheuerle A, Pala A, Thal D, Wirtz CR, Konig R (2017) Histopathological insights on imaging results of Intraoperative Magnetic Resonance Imaging, 5-Aminolevulinic acid, and intraoperative ultrasound in Glioblastoma surgery. Neurosurgery 81:165–174. https://doi.org/10.1093/neuros/nyw143

Article  PubMed  Google Scholar 

Karschnia P, Vogelbaum MA, van den Bent M, Cahill DP, Bello L, Narita Y, Berger MS, Weller M, Tonn JC (2021) Evidence-based recommendations on categories for extent of resection in diffuse glioma. Eur J Cancer 149:23–33. https://doi.org/10.1016/j.ejca.2021.03.002

Article  PubMed  Google Scholar 

Karschnia P, Young JS, Dono A, Hani L, Sciortino T, Bruno F, Juenger ST, Teske N, Morshed RA, Haddad AF, Zhang Y, Stoecklein S, Weller M, Vogelbaum MA, Beck J, Tandon N, Hervey-Jumper S, Molinaro AM, Ruda R, Bello L, Schnell O, Esquenazi Y, Ruge MI, Grau SJ, Berger MS, Chang SM, van den Bent M, Tonn JC (2023) Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group. Neuro Oncol 25:940–954. https://doi.org/10.1093/neuonc/noac193

Article  CAS  PubMed  Google Scholar 

Sattari SA, Rincon-Torroella J, Sattari AR, Feghali J, Yang W, Kim JE, Xu R, Jackson CM, Mukherjee D, Lin SC, Gallia GL, Comair YG, Weingart J, Huang J, Bettegowda C (2024) Awake Versus Asleep Craniotomy for patients with eloquent glioma: a systematic review and Meta-analysis. Neurosurgery 94:38–52. https://doi.org/10.1227/neu.0000000000002612

Article  PubMed  Google Scholar 

Haddad AF, Young JS, Morshed RA, Berger MS (2022) FLAIRectomy: resecting beyond the contrast Margin for Glioblastoma. Brain Sci 12. https://doi.org/10.3390/brainsci12050544

Molinaro AM, Hervey-Jumper S, Morshed RA, Young J, Han SJ, Chunduru P, Zhang Y, Phillips JJ, Shai A, Lafontaine M, Crane J, Chandra A, Flanigan P, Jahangiri A, Cioffi G, Ostrom Q, Anderson JE, Badve C, Barnholtz-Sloan J, Sloan AE, Erickson BJ, Decker PA, Kosel ML, LaChance D, Eckel-Passow J, Jenkins R, Villanueva-Meyer J, Rice T, Wrensch M, Wiencke JK, Oberheim Bush NA, Taylor J, Butowski N, Prados M, Clarke J, Chang S, Chang E, Aghi M, Theodosopoulos P, McDermott M, Berger MS (2020) Association of Maximal Extent of Resection of contrast-enhanced and non-contrast-enhanced Tumor with Survival within Molecular subgroups of patients with newly diagnosed Glioblastoma. JAMA Oncol 6:495–503. https://doi.org/10.1001/jamaoncol.2019.6143

Article